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Background:  We report the results of echocardiography with myocardial strain imaging and cardiac biomarkers to evaluate cardiac safety 
in a phase II study of paclitaxel with trastuzumab and pertuzumab (THP) for HER2+ metastatic breast cancer.
methods:  Sixty-nine pts with metastatic HER2+ breast cancer were enrolled and treated with THP without anthracyclines. Cardiac 
evaluation consisted of echocardiograms (TTE) with myocardial strain imaging performed every 3 months. Troponin-I and brain natriuretic 
peptide were measured immediately pre- and post- treatment every 6 weeks for 9 months. A cardiac event (CE) was defined as 
symptomatic left ventricular systolic dysfunction or possible/probable cardiac death.
results:  All 69 enrolled pts had a baseline TTE with left ventricular ejection fraction (LVEF) > 50%; follow-up TTE was available at 6 
months in 60 pts and at 12 months in 41 pts. Overall, mean LVEF remained unchanged from baseline to 6 and 12 months (64 + 5% to 62 
+ 5% and 62 + 6%, respectively). Serial myocardial strain analysis was completed for the first 34 pts with adequate follow-up. Although 
mean global longitudinal strain (GLS) was not significantly decreased from baseline to 6 and 12 months of therapy (-19.1 + 2.3% to -18.0 + 
2.0% and -18.2 + 2.5%, respectively), abnormal GLS (> -16%) was observed during treatment in 10 of 34 patients. One patient with a prior 
history of severe heart failure discontinued anti-HER2 therapy due to an asymptomatic decline in LVEF. There were no confirmed CEs at a 
median follow-up of 21 months (3-38 months). Troponin-I was undetectable in all patients, and no increase in brain natriuretic peptide was 
observed post-treatment.
conclusion:  The only clinically significant change in LVEF during THP was observed in a patient with prior history of severe heart failure. 
Although subclinical abnormalities in left ventricular systolic function were detected by GLS during dual anti-HER2 therapy, the clinical 
significance of these changes remains to be determined. Frequent serial cardiac surveillance during THP therapy in the absence of 
anthracyclines may be unnecessary among patients without significant cardiac history.
